The cognitive impairment in AD closely parallels the loss of synapses due to the toxic effects of Aβ, tau, and inflammation; thus, emerging biomarkers are able to measure synapse injury and loss in the brain and may correlate with cognitive function in AD [26]. The gene discussed is MAPT; the disease is Cognitive impairment.